Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders

OBJECTIVE: The T1GER (A Study of SIMPONI to Arrest β-Cell Loss in Type 1 Diabetes) study showed many metabolic benefits of the tumor necrosis factor-α blocker golimumab in children and young adults with type 1 diabetes (T1D). Off-therapy effects are reported. RESEARCH DESIGNS AND METHODS: T1GER was...

Descripción completa

Detalles Bibliográficos
Autores principales: Rigby, Mark R., Hayes, Beverly, Li, Yinglei, Vercruysse, Frank, Hedrick, Joseph A., Quattrin, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020023/
https://www.ncbi.nlm.nih.gov/pubmed/36576974
http://dx.doi.org/10.2337/dc22-0908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020023/
https://www.ncbi.nlm.nih.gov/pubmed/36576974
http://dx.doi.org/10.2337/dc22-0908

Ejemplares similares